npj Breast Cancer · 2024 · 43 citations · 71 references
MedicineMolecular MedicineOncologyMetastasisMolecular DiagnosticsMolecular OncologyBiomarker ValidationCancer BiomarkersCancer Molecular DiagnosticsCirculating Tumor CellsCirculating Tumor Dna AnalysisMetastatic Breast CancerCirculating Tumor BiomarkersCirculating Tumor Dna DetectionCirculating Tumor Dna TestingCirculating Tumor MarkersMetastatic Breast Cancer TreatmentMolecular Drug ResistanceMolecular GenotypingTumor Genotyping
Following the first characterization of circulating tumor DNA (ctDNA) in the 1990s, recent advances led to its introduction in the clinics. At present, the European Society Of Medical Oncology (ESMO) recommendations endorse ctDNA testing in routine clinical practice for tumor genotyping to direct molecularly targeted therapies in patients with metastatic cancer. In studies on metastatic breast cancer, ctDNA has been utilized for treatment tailoring, tracking mechanisms of drug resistance, and for predicting disease response before imaging. We review the available evidence regarding ctDNA applications in metastatic breast cancer.
71
Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto et al. · Journal of Clinical Oncology · 2019 · 3K citations · Full text
Life Sciences, Immunology, Oncology +17
Circulating mutant DNA to assess tumor dynamics
Frank Diehl, Kerstin Schmidt, Michael A. Choti et al. · Nature Medicine · 2008 · 2.7K citations · Full text
OncoKB: A Precision Oncology Knowledge Base
Debyani Chakravarty, Jianjiong Gao, Sarah Phillips et al. · JCO Precision Oncology · 2017 · 2.7K citations
Alpelisib for <i>PIK3CA</i> -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Fabrice André, Eva Ciruelos, Gábor Rubovszky et al. · New England Journal of Medicine · 2019 · 2.6K citations · Full text
Medicine, Oncology, Pharmacology +17
Aurélien Marabelle, Marwan Fakih, Juanita Lopez et al. · The Lancet Oncology · 2020 · 2.5K citations · Full text
Medicine, Oncology, Pharmacotherapy +17